



Current as of October 26, 2022

Short Talks Selected from Proffered Abstracts

Oncogenes and Tumor Suppressor Genes

PR001 Mechanisms by which Mito-LND inhibits KRAS mutant lung cancer. Katherine Weh. University of Michigan, Ann Arbor, Michigan, USA.

Clinical Trials

PR002 A pilot study of a MUC1 vaccine in current and former smokers at high risk for lung cancer. Arjun Pennathur. University of Pittsburgh School of Medicine, Pittsburgh, PA,

Biology of Preneoplasia, Invasion, and Progression

PR003 Multiplexed immune phenotyping and miRNA-ISH in bronchial premalignant lesions reveals a mechanism of immune suppression. Darren J. Chiu, Department of Medicine, Boston University School of Medicine, Boston, MA,

PR004 The role of NOTCH1 in bronchial pre-malignant lesions. Roxana Michaela Pfefferkorn, Boston University, Boston, MA.

Bioinformatics, Convergence Science, and Systems Biology

PR005 Features and susceptibility to dietary-induced alkylating damage in colorectal cancer. Marios Giannakis. Dana-Farber Cancer Institute, Boston, MA.

Radiology and Imaging

PR006 Screening under-served populations by mobile low dose computerized tomography (LDCT) scans results in stage shift with potential cures: Time for a change in health policy? Derek Raghavan. Atrium Health Levine Cancer Institute, Charlotte, North Carolina, USA.

Liquid Biopsies: Circulating DNA, Circulating Tumor Cells

PR007 A liposomal priming agent increases the sensitivity of liquid biopsies. Maria Martin Alonso. Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

Gene Discovery and Characterization, Including GWAS, Post-GWAS, Sequencing

PR008 Development and testing of a polygenic risk score for breast cancer. Aggressiveness. Yiwey Shieh, Weill Cornell Medicine, New York, NY,